Pfizer to Cut $3.5B in Costs, Close NJ Plant
b'
There was a time when the world was heavy with anticipation for COVID vaccines and boosters \\u2014 to the point where desperate consumers were lining up for their chance for an inoculation that was tantamount, for many, to a \\u201cget out of quarantine free card.\\u201d
But three years past the initial panic of the COVID-19 pandemic, and two years into mass vaccinations, things have stabilized. And while most of it is good for humankind, pharma companies at the forefront of these solutions are now facing some sluggish demand.
Download and listen to the audio version below and click here to subscribe to the Today in Manufacturing podcast.
'